What is Wedbush’s Forecast for GLUE Q4 Earnings?

Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) – Investment analysts at Wedbush issued their Q4 2026 earnings per share estimates for shares of Monte Rosa Therapeutics in a research report issued to clients and investors on Thursday, May 8th. Wedbush analyst R. Driscoll expects that the company will post earnings of ($0.57) per share for the quarter. Wedbush currently has a “Outperform” rating and a $17.00 price target on the stock. The consensus estimate for Monte Rosa Therapeutics’ current full-year earnings is ($1.49) per share.

Monte Rosa Therapeutics (NASDAQ:GLUE) last issued its earnings results on Thursday, May 8th. The company reported $0.57 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.24) by $0.81.

A number of other brokerages also recently weighed in on GLUE. Wells Fargo & Company lowered their price target on Monte Rosa Therapeutics from $11.00 to $10.00 and set an “equal weight” rating on the stock in a report on Friday, March 21st. Lifesci Capital began coverage on Monte Rosa Therapeutics in a report on Wednesday, March 12th. They set an “outperform” rating and a $19.00 price target on the stock.

Monte Rosa Therapeutics Trading Down 2.6%

Shares of GLUE stock opened at $4.11 on Monday. Monte Rosa Therapeutics has a 1-year low of $3.21 and a 1-year high of $12.40. The company has a market capitalization of $252.81 million, a price-to-earnings ratio of -2.25 and a beta of 1.52. The stock’s fifty day simple moving average is $5.05 and its 200-day simple moving average is $6.54.

Insider Buying and Selling at Monte Rosa Therapeutics

In other news, Director Chandra P. Leo bought 10,000 shares of the stock in a transaction on Monday, March 24th. The shares were purchased at an average price of $5.84 per share, for a total transaction of $58,400.00. Following the completion of the purchase, the director now directly owns 10,000 shares of the company’s stock, valued at $58,400. This trade represents a ∞ increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 6.90% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of GLUE. Tower Research Capital LLC TRC grew its stake in Monte Rosa Therapeutics by 192.8% in the fourth quarter. Tower Research Capital LLC TRC now owns 5,443 shares of the company’s stock valued at $38,000 after purchasing an additional 3,584 shares in the last quarter. GAMMA Investing LLC grew its stake in Monte Rosa Therapeutics by 10,665.5% in the fourth quarter. GAMMA Investing LLC now owns 5,921 shares of the company’s stock valued at $41,000 after purchasing an additional 5,866 shares in the last quarter. BNP Paribas Financial Markets purchased a new position in Monte Rosa Therapeutics in the fourth quarter valued at about $43,000. Virtus ETF Advisers LLC purchased a new position in Monte Rosa Therapeutics in the fourth quarter valued at about $63,000. Finally, Focus Partners Wealth acquired a new stake in shares of Monte Rosa Therapeutics in the fourth quarter worth about $77,000. Hedge funds and other institutional investors own 79.96% of the company’s stock.

Monte Rosa Therapeutics Company Profile

Monte Rosa Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops MRT-2359, an orally bioavailable molecular glue degrader targeting the translation termination factor protein GSPT1 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of systemic and central nervous system autoimmune diseases; and MRT-8102 for the treatment of IL-1?/NLRP3 driven inflammatory diseases.